"The Maintenance Treatment of ITIVA in AML Patients"

"Patients in arm1 were randomly divided into two groups, namely the interference'- α- 1b, interleukin-2, thalidomide treatment group and the VA treatment group. After receiving a two cycle protocol, patients were evaluated for the endpoint of the trial and their MRD conversion rate was calculated.~Patients in arm2 will receive triple maintenance treatment, completing three alternative regimens into one cycle. The regimen maintenance treatment will be maintained for a total of 8 cycles. Each medication regimen takes 28 days as a cycle. The number of days administered per cycle can be adjusted based on the patient's blood count."